Inactive

Development of Novel Nanotherapeutics to Combat Pneumonic Plague

Inactive

The Government has a requirement for the development of novel nanotherapeutic approaches targeting outer membrane proteins utilizing camelid single-domain antibodies and bovine-derived ultralong CDR3 ... The Government has a requirement for the development of novel nanotherapeutic approaches targeting outer membrane proteins utilizing camelid single-domain antibodies and bovine-derived ultralong CDR3 antibody structures (e.g., BamA, LptD, and Ail) of virulent Yersinia pestis for the treatment of pneumonic plague for assessment in in vitro and in vivo assays. The Government intends to award an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for novel nanotherapeutic approaches targeting outer membrane proteins for the treatment of pneumonic plague (and potentially other infectious microbial organisms or toxins) for assessment in in vitro and in vivo assays support. These services include, but are not limited to production of high-quality recombinant proteins from bacteria, viruses, or toxins; vaccinating appropriate animal species (i.e. camelids and bovines) to generate the material needed to engineer completely novel nanotherapeutics; perform in vitro testing of nanotherapeutic characteristics in order to refine molecules and promote down-selection, provide material in sufficient quantity and appropriate quality for in vitro and in vivo studies (e.g. mice and non-human primates), engineer or formulate down-selected nanotherapeutics for different routes of administration in vivo (e.g., intramuscular or intravenous, etc.).